$XBI $140 +1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$AMPE +3% Phase 1 data for AP-014 for respiratory distress in patients as a result of COVID-19. source
Pipeline Updates
$XNCR +2% Doses first patient in ph 1 study of XmAb564 for autoimmune diseases in healthy volunteers. source
$GRTX +32% Updated ph 1/2 pilot study data supports ph 2 initiation planned for H1 2021. source
$ADVM -48% Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony found in ph 2 INFINITY study, company unmasked data and is analyzing. source
$NKTX -1% IND cleared for NKX019 for R/R B cell malignancies. source
$AKTX -2% Nomacopan granted Fast Track Designation by FDA for BP. source
$GTHX -1% Initiation of ph 3 pivotal study of Cosela for mTNBC. source
$ADMA +8% FDA approved increased manufacturing processes for BIVIGAM. source
$TRIL -7% Provides data for ph 1 TTI-662 and TTI-621, and update for phase 1b/2 programs in hematologic and solid tumor indications, first patient dosed in ph 1b/2 of TTI-662 combo for R/R MM. source
$CALT +4% FDA accepted NDA and granted priority review for Nefecon for the treatment of IgA nephropathy (IgAN). PDUFA target date has been set for 9/15/21. source
$PLX -35% CRL received base on FDA unable to conduct facility inspection in Israel due to travel restrictions. Company will request Type-A meeting with FDA. source
Finance Updates
$NYMX -15% $8M private placement at $2.18/share. source